Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients

Figure 1 Sensitivity of nested polymerase chain reaction assay to tumor-specific markers in hepatocellular carcinoma cell lines. Lanes 1-4: 1 × 10³, 1 × 10², 1 × 10¹ and 1 × 10⁰ hepatoma cells detected by nested reverse transcripts-polymerase chain reaction using melanoma antigen-1 (MAGE-1), synovial sarcoma X breakpoint-1 (SSX-1), cancer-testis-associated protein of 11 kDa (CTp11), and β2-microglobin; Lane 5: Peripheral blood mononuclear cells (PBMC) from healthy donors only; Lane 6: negative control; Lane M: Molecular marker, 100 bp DNA ladder (Gibco).

Figure 2 Electrophoresis of second round polymerase chain reaction products amplified from cDNA of peripheral blood mononuclear cells samples. Lane M: Molecular marker, 100 bp DNA ladder (Gibco); Lane P: Positive control; Lane B: Blank control; lane Β2-MG (335 bp) as cDNA quality control; Lanes 1, 5, 8, 11: Positive melanoma antigen-1 (MAGE-1) transcript; Lanes 1, 4, 9: Positive synovial sarcoma X breakpoint-1 (SSX-1) transcript; Lanes 1, 3, 7, 12: Positive cancer-testis-associated protein of 11 kDa (CTp11) transcript; Lanes 2, 6 and 10: Negative transcript of all three CTA genes.